• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CiToxLAB acquires AccelLAB, a preclinical medical devices CRO

CiToxLAB acquires AccelLAB, a preclinical medical devices CRO

November 9, 2016
CenterWatch Staff

CiToxLAB, a preclinical CROs, has announced the acquisition of AccelLAB, a Canadian CRO specialized in the preclinical assessment of new medical devices. Through this acquisition, CiToxLAB Group reinforces its position in the non-clinical CRO arena and enlarges its services portfolio to medical devices, a fast growing area which offers large synergies with drug development, the CiToxLAB’s core business.

AccelLAB was founded in 2004 by Dr. Guy Leclerc, an Interventional Cardiologist who headed the department of Cardiology and Cardiac Surgery of the Centre Hospitalier de l’Université de Montreal (CHUM). As an interventional cardiologist practitioner, Guy Leclerc has been a pioneer in applying what we call today translational research in the field of medical devices, helping client companies in the development of new cardiac stents, valves, pacemakers, etc. The services were more recently enlarged to other areas such as orthopedic, ENT (Ear, Nose and Throat) and dermatology specialties.

AccelLAB has a staff of around 100 people and the facilities include operating rooms, in particular for cardiac catheterization, state-of-the-art laboratories, a large vivarium, a medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories.

Dr. Jean-François Le Bigot, chairman and CEO of CiToxLAB Group, said, “We identified AccelLAB as a strategic target to make our group a more global services player in the Life Sciences Services arena. Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers in particular in the cardiovascular, orthopedic fields and more generally in the regenerative medicine. We have been convinced by the high scientific approaches of AccelLAB, the depth of itsmethods and technologies combined with strict regulatory compliance but also, by the personality of the founder Guy Leclerc who is so committed himself to the progress in translational research with a strong entrepreneurship spirit.”

Following this acquisition, Dr. Guy Leclerc remains the managing director of AccelLAB. CiToxLAB continues its growth strategy and becomes a group with more than 1.000 staff in four countries (France, Canada, Hungary and Denmark) and revenues upper to €100 million realized for more than a third in North America.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing